| Identification | Back Directory | [Name]
eCF506 | [CAS]
1914078-41-3 | [Synonyms]
eCF506
ECF506; ECF-506; ECF 506.
Carbamic acid, N-[4-[4-amino-1-[2-[4-(dimethylamino)-1-piperidinyl]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester | [Molecular Formula]
C26H38N8O3 | [MDL Number]
MFCD31657410 | [MOL File]
1914078-41-3.mol | [Molecular Weight]
510.63 |
| Chemical Properties | Back Directory | [Boiling point ]
650.3±55.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:15.0(Max Conc. mg/mL);29.38(Max Conc. mM)
Ethanol:15.0(Max Conc. mg/mL);29.38(Max Conc. mM) | [form ]
A crystalline solid | [pka]
12.60±0.70(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
eCF506, induces a very potent antiproliferative effect in both MCF7 and MDA-MB-231 cells. eCF506 inhibits phosphorylation of SRC and FAK at low nanomolar levels, with complete inhibition observed at 100 nM. | [in vivo]
eCF506 shows a moderate oral bioavailability (25.3%). A significant reduction of phospho-SRCY416 is observed in the xenograft sections from mice treated with eCF506 relative to the untreated animal controls[1]. |
|
|